Skip to content

Ceftazidime

FDA-approved product (injectable, injection), marketed as Ceftazidime, Ceftazidime In Dextrose Container, Ceptaz and 7 more.

Registered studies
50+
Lab records
324
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Ceftazidime
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial disease
  • Infection
  • Parametritis
  • Peritonitis
  • Pneumonia
  • Pyelonephritis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Third-generation cephalosporins
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01DD02

Repurposing investigation

Ceftazidime is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA94.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae60.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis53.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 5 of 5 lab records
  • E. coli: measured active in 41 of 47 lab records
  • K. pneumoniae: measured active in 111 of 272 lab records
Show the latest 150 of 324 laboratory records, with sources

Loading records…

Every record is in ChEMBL, linked above. “Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ceftazidime with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).

    NCT02475733 · start 2015-08-01

    Registered record
    Registry ID
    NCT02475733
    Conditions
    Complicated Intra-abdominal Infections
    Interventions
    Ceftazidime -avibactam; Meropenem; Metronidazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-08-01
    Completion
    2017-06-01
    Enrolment
    83

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Intra-abdominal Infections
    InterventionCeftazidime -avibactam; Meropenem; Metronidazole
    PhasePhase 2
    Registry statusCompleted
  • Comparing Cefepime Versus Cefazolin Plus Ceftazidime for CAPD-associated Peritonitis

    NCT02872038 · start 2015-08

    Registered record
    Registry ID
    NCT02872038
    Conditions
    Peritoneal Dialysis Associated Peritonitis
    Interventions
    Cefepime; Cefazolin plus Ceftazidime
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-08
    Completion
    2016-11-30
    Enrolment
    154

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeritoneal Dialysis Associated Peritonitis
    InterventionCefepime; Cefazolin plus Ceftazidime
    PhasePhase 4
    Registry statusCompleted
  • A Phase I Study to Assess the Safety, Tolerability and PK of Ceftazidime-Avibactam in Healthy Chinese Subjects

    NCT01920399 · start 2013-10

    Registered record
    Registry ID
    NCT01920399
    Conditions
    Healthy Volunteers
    Interventions
    CAZ-AVI; 0.9% Normal Saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-10
    Completion
    2013-11
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionCAZ-AVI; 0.9% Normal Saline
    PhasePhase 1
    Registry statusCompleted
  • A Study to Investigate the Effect of Administration of Ceftazidime-avibactam (CAZ-AVI) and Ceftaroline Fosamil -Avibactam (CXL) on the Intestinal Flora of Healthy Volunteers

    NCT01789528 · start 2013-08

    Registered record
    Registry ID
    NCT01789528
    Conditions
    Pharmacokinetics; Open Label; CAZ-AVI; CXL; Effect on Intestinal Flora; Safety
    Interventions
    CAZ-AVI; CXL
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2013-08
    Completion
    2014-03
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPharmacokinetics; Open Label; CAZ-AVI; CXL +2 more
    InterventionCAZ-AVI; CXL
    PhasePhase 1
    Registry statusCompleted
  • Pharmacokinetics of Selected Antiinfectives During Sustained Low-efficiency Dialysis (SLED)

    NCT02287493 · start 2013-07

    Registered record
    Registry ID
    NCT02287493
    Conditions
    Replacement Therapy, Renal
    Interventions
    Pharmacokinetic Analysis
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2013-07
    Completion
    2016-12
    Enrolment
    35

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionReplacement Therapy, Renal
    InterventionPharmacokinetic Analysis
    PhaseNot recorded
    Registry statusCompleted
  • Ceftazidime-Avibactam for the Treatment of Infections Due to Ceftazidime Resistant Pathogens

    NCT01644643 · start 2013-01

    Registered record
    Registry ID
    NCT01644643
    Conditions
    Complicated Urinary Tract Infection; Complicated Intra-abdominal Infection
    Interventions
    Ceftazidime - Avibactam ( CAZ-AVI); Best Available Therapy; Metronidazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-01
    Completion
    2014-09
    Enrolment
    345

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Urinary Tract Infection; Complicated Intra-abdominal Infection
    InterventionCeftazidime - Avibactam ( CAZ-AVI); Best Available Therapy; Metronidazole
    PhasePhase 3
    Registry statusCompleted
  • Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

    NCT01595438 · start 2012-10

    Registered record
    Registry ID
    NCT01595438
    Conditions
    Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
    Interventions
    Ceftazidime - Avibactam ( CAZ-AVI); Doripenem; Either switch to oral therapy: 500 mg of Ciprofloxacin (oral); or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-10
    Completion
    2014-08
    Enrolment
    598

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
    InterventionCeftazidime - Avibactam ( CAZ-AVI); Doripenem; Either switch to oral therapy: 500 mg of Ciprofloxacin (oral); or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
    PhasePhase 3
    Registry statusCompleted
  • Ceftazidime-Avibactam Compared With Doripenem Followed by Oral Therapy for Hospitalized Adults With Complicated UTIs (Urinary Tract Infections)

    NCT01599806 · start 2012-10

    Registered record
    Registry ID
    NCT01599806
    Conditions
    Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
    Interventions
    Ceftazidime - Avibactam ( CAZ-AVI); Doripenem; Either switch to oral therapy: 500 mg of Ciprofloxacin (oral); or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-10
    Completion
    2014-08
    Enrolment
    641

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis
    InterventionCeftazidime - Avibactam ( CAZ-AVI); Doripenem; Either switch to oral therapy: 500 mg of Ciprofloxacin (oral); or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)
    PhasePhase 3
    Registry statusCompleted
  • Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections

    NCT01499290 · start 2012-03

    Registered record
    Registry ID
    NCT01499290
    Conditions
    Complicated Intra-Abdominal Infection
    Interventions
    CAZ-AVI; Metronidazole; Meropenem
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-03
    Completion
    2014-04
    Enrolment
    493

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Intra-Abdominal Infection
    InterventionCAZ-AVI; Metronidazole; Meropenem
    PhasePhase 3
    Registry statusCompleted
  • A Study to Assess the Levels of CAZ-AVI and Metronidazole in the Blood When Given Together and Separately

    NCT01534247 · start 2012-02

    Registered record
    Registry ID
    NCT01534247
    Conditions
    Healthy
    Interventions
    CAZ-AVI; metronidazole; CAZ-AVI + metronidazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-02
    Completion
    2012-07
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCAZ-AVI; metronidazole; CAZ-AVI + metronidazole
    PhasePhase 1
    Registry statusCompleted
  • Pharmacokinetic Assessment of Ceftazidime in Intermittent Hemodialysis Patients

    NCT01507532 · start 2012-01

    Registered record
    Registry ID
    NCT01507532
    Conditions
    Renal Failure
    Interventions
    pharmacokinetic monitoring
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2012-01
    Completion
    2016-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Failure
    Interventionpharmacokinetic monitoring
    PhasePhase 4
    Registry statusWithdrawn
  • A Study to Assess the Levels of Two Antibiotics in the Blood When Given Together and Separately

    NCT01430910 · start 2011-09

    Registered record
    Registry ID
    NCT01430910
    Conditions
    Healthy
    Interventions
    CAZ104; Avibactam; Ceftazidime
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-09
    Completion
    2012-10
    Enrolment
    43

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCAZ104; Avibactam; Ceftazidime
    PhasePhase 1
    Registry statusCompleted
  • Population Pharmacokinetics of Anti-infectious Drugs in Children

    NCT01344512 · start 2011-06

    Registered record
    Registry ID
    NCT01344512
    Conditions
    Pediatrics; Ceftazidime; Ciprofloxacin; Voriconazole
    Interventions
    Ceftazidime; Ciprofloxacin; Voriconazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2011-06
    Completion
    2014-09
    Enrolment
    214

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPediatrics; Ceftazidime; Ciprofloxacin; Voriconazole
    InterventionCeftazidime; Ciprofloxacin; Voriconazole
    PhaseNot applicable
    Registry statusCompleted
  • Safety and Efficacy of IV CXA-101 and IV Ceftazidime in Patients With Complicated Urinary Tract Infections

    NCT00921024 · start 2009-06-30

    Registered record
    Registry ID
    NCT00921024
    Conditions
    Complicated Urinary Tract Infection
    Interventions
    CXA-101; Ceftazidime
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2009-06-30
    Completion
    2010-03-11
    Enrolment
    129

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionComplicated Urinary Tract Infection
    InterventionCXA-101; Ceftazidime
    PhasePhase 2
    Registry statusCompleted
  • Prospective Randomized Evaluation of Antibiotic Regimen Following Appendectomy for Perforated Appendicitis

    NCT00195923 · start 2005-04

    Registered record
    Registry ID
    NCT00195923
    Conditions
    Perforated Appendicitis
    Interventions
    Ampicillin, gentamicin, clindamycin, flagyl, ceftazidime
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2005-04
    Completion
    2007-01
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPerforated Appendicitis
    InterventionAmpicillin, gentamicin, clindamycin, flagyl, ceftazidime
    PhaseNot recorded
    Registry statusCompleted